Ocrelizumab versus placebi in primary progressive multiplesclerosis
In the phase 3 trial 732 patients were randomly assigned with primary progressive multiple sclerosis in a 2:1 ratio to receive intravenous ocrelizumab or placebo every 24 weeks for at least 120 weeks and until a prespecified number of confirmed disability progression events had occurred.Neoplasms occurred in 2.3% of patients who received ocrelizumab and in 0.8% of patients who received placebo. Among patients with primary progressive multiple sclerosis, ocrelizumab was associated with lower rates of clinical and MRI progression than placebo..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:376 |
|---|---|
| Enthalten in: |
The New England journal of medicine - 376(2017), 3, Seite 209 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kappos, L [VerfasserIn] |
|---|
| BKL: | |
|---|---|
| Themen: |
Care and treatment |
| RVK: |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
OLC1991145217 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1991145217 | ||
| 003 | DE-627 | ||
| 005 | 20230512152341.0 | ||
| 007 | tu | ||
| 008 | 170303s2017 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a PQ20170501 |
| 035 | |a (DE-627)OLC1991145217 | ||
| 035 | |a (DE-599)GBVOLC1991145217 | ||
| 035 | |a (PRQ)g543-62cf30a68c2af4ad65a2e1838a96fc4a0d1eb01dba06968c0b01bf6b3724909e0 | ||
| 035 | |a (KEY)0171808820170000376000300209ocrelizumabversusplacebiinprimaryprogressivemultip | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DNB |
| 084 | |a XA 10000 |q AVZ |2 rvk | ||
| 084 | |a 44.60 |2 bkl | ||
| 084 | |a 44.00 |2 bkl | ||
| 100 | 1 | |a Kappos, L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Ocrelizumab versus placebi in primary progressive multiplesclerosis |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a In the phase 3 trial 732 patients were randomly assigned with primary progressive multiple sclerosis in a 2:1 ratio to receive intravenous ocrelizumab or placebo every 24 weeks for at least 120 weeks and until a prespecified number of confirmed disability progression events had occurred.Neoplasms occurred in 2.3% of patients who received ocrelizumab and in 0.8% of patients who received placebo. Among patients with primary progressive multiple sclerosis, ocrelizumab was associated with lower rates of clinical and MRI progression than placebo. | ||
| 650 | 4 | |a Comparative analysis | |
| 650 | 4 | |a Diagnosis | |
| 650 | 4 | |a Monoclonal antibodies | |
| 650 | 4 | |a Multiple sclerosis | |
| 650 | 4 | |a Health aspects | |
| 650 | 4 | |a Care and treatment | |
| 650 | 4 | |a Placebos | |
| 650 | 4 | |a Patients | |
| 650 | 4 | |a Usage | |
| 700 | 1 | |a Montalban, X |4 oth | |
| 700 | 1 | |a Bar-Or, A |4 oth | |
| 700 | 1 | |a Wolinsky, J.S |4 oth | |
| 700 | 1 | |a Arnold, D.L |4 oth | |
| 700 | 1 | |a Hauser, S.L |4 oth | |
| 700 | 1 | |a Mairon, N |4 oth | |
| 700 | 1 | |a Garren, H |4 oth | |
| 700 | 1 | |a Belachew, S |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t The New England journal of medicine |d Waltham, Mass. : MMS, 1928 |g 376(2017), 3, Seite 209 |w (DE-627)129495220 |w (DE-600)207154-X |w (DE-576)014893169 |x 0028-4793 |7 nnns |
| 773 | 1 | 8 | |g volume:376 |g year:2017 |g number:3 |g pages:209 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_168 | ||
| 912 | |a GBV_ILN_183 | ||
| 912 | |a GBV_ILN_290 | ||
| 912 | |a GBV_ILN_2004 | ||
| 912 | |a GBV_ILN_2006 | ||
| 912 | |a GBV_ILN_2008 | ||
| 912 | |a GBV_ILN_2021 | ||
| 912 | |a GBV_ILN_2219 | ||
| 912 | |a GBV_ILN_2414 | ||
| 912 | |a GBV_ILN_2424 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4126 | ||
| 912 | |a GBV_ILN_4219 | ||
| 912 | |a GBV_ILN_4256 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 912 | |a GBV_ILN_4310 | ||
| 912 | |a GBV_ILN_4315 | ||
| 912 | |a GBV_ILN_4320 | ||
| 912 | |a GBV_ILN_4323 | ||
| 936 | r | v | |a XA 10000 |
| 936 | b | k | |a 44.60 |q AVZ |
| 936 | b | k | |a 44.00 |q AVZ |
| 951 | |a AR | ||
| 952 | |d 376 |j 2017 |e 3 |h 209 | ||